Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

418018

registered interest
date	09/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Plasma Resources
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much his Department has received to date from the sale of Plasma Resource UK Ltd.
tabling member constituency	Kingston upon Hull North
tabling member printed	Diana Johnson
uin	9676
answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>The Department sold 80% of Plasma Resources UK Ltd on 31 July 2013. Government received £88.6 million on completion together with deferred consideration as announced at the time of the sale.</p><p> </p><p> </p><p> </p><p>Further information is already available on the gov.uk website at:</p><p> </p><p><em> </em></p><p> </p><p><a href="https://www.gov.uk/government/news/minister-welcomes-bain-capital-buying-majority-stake-in-pruk" target="_blank">https://www.gov.uk/government/news/minister-welcomes-bain-capital-buying-majority-stake-in-pruk</a></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 14:41:18 answering member 4020 label Biography information for George Freeman
tabling member	1533 label Biography information for Dame Diana Johnson

418048

registered interest
date	09/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer Drugs Fund
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the administrative cost was of the Cancer Drugs Fund re-evaluation process in 2014-15.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9754
answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>NHS England has advised that this information is not available given the multi-disciplinary nature of the Cancer Drugs Fund re-evaluation process and the involvement of different parts of the National Health Service.</p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 08:56:08 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

418049

registered interest
date	09/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what discussions he has had with NHS England on how the survival rates for pancreatic cancer are reflected in assessments of new treatments for that disease.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9823
answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>We have had no such discussions.</p><p> </p><p> </p><p> </p><p>NHS England assesses new cancer drugs for inclusion on the national Cancer Drugs Fund (CDF) list in accordance with its CDF Standard Operating Procedures, which are available at:</p><p> </p><p> </p><p> </p><p><a href="http://www.england.nhs.uk/ourwork/pe/cdf/cdf-sop/" target="_blank">www.england.nhs.uk/ourwork/pe/cdf/cdf-sop/</a></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 14/09/2015 14:43:49 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

418085

registered interest
date	09/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Myeloma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether his Department plans to make lenalidomide available after the Patient Access Scheme for second line treatment is approved.
tabling member constituency	Brigg and Goole
tabling member printed	Andrew Percy
uin	9753
answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>Ministers are responsible for agreeing whether a patient access scheme (PAS) proposal can be considered in the development of guidance by the National Institute for Health and Care Excellence (NICE), taking advice from the Patient Access Scheme Liaison Unit at NICE into account. It is then for NICE to consider the PAS proposal alongside other evidence in determining whether the technology represents a clinical and cost effective use of National Health Service resources taking into account.</p><p> </p><p> </p><p> </p><p>In line with the provisions of the 2014 Pharmaceutical Price Regulation Scheme, discussions about patient access scheme proposals are confidential until a proposal is considered in the development of NICE guidance.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9752 question first answered 14/09/2015 14:47:08 answering member 4020 label Biography information for George Freeman
tabling member	3939 label Biography information for Andrew Percy

418086

registered interest
date	09/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Multiple Myeloma: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, when NICE plans to approve the Patient Access Scheme for second line treatment with lenalidomide for patients with multiple myeloma.
tabling member constituency	Brigg and Goole
tabling member printed	Andrew Percy
uin	9752
answer	answer is ministerial correction date of answer 14/09/2015 answer text <p>Ministers are responsible for agreeing whether a patient access scheme (PAS) proposal can be considered in the development of guidance by the National Institute for Health and Care Excellence (NICE), taking advice from the Patient Access Scheme Liaison Unit at NICE into account. It is then for NICE to consider the PAS proposal alongside other evidence in determining whether the technology represents a clinical and cost effective use of National Health Service resources taking into account.</p><p> </p><p> </p><p> </p><p>In line with the provisions of the 2014 Pharmaceutical Price Regulation Scheme, discussions about patient access scheme proposals are confidential until a proposal is considered in the development of NICE guidance.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman grouped question UIN 9753 question first answered 14/09/2015 14:47:08 answering member 4020 label Biography information for George Freeman
tabling member	3939 label Biography information for Andrew Percy

417657

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the level of provision of pancreatic cancer treatment on the NHS; and if he will make a statement.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9405
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>Over the last 15 years, services for pancreatic cancer have been significantly strengthened within the National Health Service. This includes clearer diagnostic pathways, decision making by specialist multi-disciplinary teams and centralisation of pancreas surgery within specialist teams.</p><p> </p><p> </p><p> </p><p>Between 1999 and 2009, following reorganisation of pancreas services, there are now twice as many patients accessing surgery, and one year survival has increased by 5%. The benefits of the United Kingdom model are recognised internationally.</p><p> </p><p> </p><p> </p><p>It is recognised that pancreatic cancer is a challenging disease for a number of reasons. There is a lack of any effective drug therapies and research opportunities are restricted by the small number of patients with the disease (approximately 7,000 annually), and the relatively low survival rates.</p><p> </p><p> </p><p> </p><p>Symptoms are variable and difficult to identify, and there is presently no diagnostic test, although a test is in the research phase.</p><p> </p><p> </p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p><p><strong> </strong></p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/09/2015 12:25:49 answering member 3918 label Biography information for Jane Ellison
tabling member	1538 label Biography information for Rosie Cooper

417658

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pancreatic Cancer: Drugs
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure that expert clinicians are consulted when assessing new treatments for pancreatic cancer.
tabling member constituency	West Lancashire
tabling member printed	Rosie Cooper
uin	9406
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The National Institute for Health and Care Excellence’s (NICE) guidance is based on a thorough assessment of the available evidence and is developed through wide consultation with stakeholders. NICE makes every effort to ensure that appropriate stakeholders, including clinical experts, are able to engage with the development of its guidance.</p><p> </p><p> </p><p> </p><p>As part of NICE’s technology appraisal process, clinical specialists, commissioning experts and patient experts are invited by the Appraisal Committee to provide written evidence and attend the Committee meeting to help in the Committee's discussion of the technology being appraised.</p><p> </p><p> </p><p> </p><p>NHS England is responsible for administering the Cancer Drugs Fund (CDF) and decisions on which treatments are included on the national CDF list are made by the CDF clinical panel. The panel includes expert oncologists, oncology pharmacists and patient representatives.</p><p> </p><p> </p><p> </p> answering member constituency Mid Norfolk answering member printed George Freeman question first answered 11/09/2015 11:55:39 answering member 4020 label Biography information for George Freeman
tabling member	1538 label Biography information for Rosie Cooper

417659

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Nurses: Training
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the cost to the public purse of training a UK citizen as a nurse; and what assessment he has made of how this figure compares with the costs of recruiting nurses from overseas.
tabling member constituency	Twickenham
tabling member printed	Dr Tania Mathias
uin	9401
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The Personal Social Services Research Unit at the University of Kent estimates that the average cost of training a nurse in 2013 was £78,604. This figure reflects the total cost of training and therefore includes costs funded through the public purse, including the NHS bursary, and by the student.</p><p> </p><p> </p><p> </p><p>National Health Service organisations are best placed to decide how many staff they employ and how best to recruit those staff to meet services tailored to the needs of their patients and local communities, to deliver safe care.</p><p> </p> answering member constituency Ipswich answering member printed Ben Gummer question first answered 11/09/2015 12:07:22 answering member 3988 label Biography information for Ben Gummer
tabling member	4404 label Biography information for Dr Tania Mathias

417660

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer: Mortality Rates
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of changes in cancer survival rates in each of the last five years.
tabling member constituency	Coventry North East
tabling member printed	Colleen Fletcher
uin	9393
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The Independent Cancer Taskforce’s new strategy, <em>Achieving World-Class Cancer Outcomes: A Strategy for England 2015-2020</em>, which recommends improvements across the cancer pathway, was published on 19 July 2015. It will reduce incidence of cancer and improve services and outcomes for cancer patients, in particular survival rates. We will work with the National Health Service, charities and patient groups to deliver it.</p><p> </p><p> </p><p> </p><p>Our cancer survival rates are at an all-time high and continue to improve, but we know we need to do more to be among the best in the world, and that is what we aim to achieve.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/09/2015 13:13:15 answering member 3918 label Biography information for Jane Ellison
tabling member	4378 label Biography information for Colleen Fletcher

417663

registered interest
date	08/09/2015
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Drugs: Misuse
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to reduce the mortality rate from drug misuse in the North East.
tabling member constituency	Middlesbrough South and East Cleveland
tabling member printed	Tom Blenkinsop
uin	9389
answer	answer is ministerial correction date of answer 11/09/2015 answer text <p>The latest rise in drug misuse deaths – particularly in the North East – is a great concern and highlights the need for further local and national action. We need to ensure the most vulnerable users can access drug treatment and harm reduction services, where they have the best chance of recovery.</p><p> </p><p> </p><p> </p><p>Public Health England will continue to support local authorities in delivering effective recovery services for everyone who needs them. They are providing local authorities and commissioners with expert advice, evidence, and management information including outcomes and value for money data. This can help to ensure that the local services are evidence-based, effective and integrated with local health, housing and employment support.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 11/09/2015 13:27:25 answering member 3918 label Biography information for Jane Ellison
tabling member	4037 label Biography information for Tom Blenkinsop